期刊文献+

抗原致敏DC联合LAK细胞对肺腺癌细胞杀伤作用的研究 被引量:2

Research on the Effect of Dendritic Cells Combined with Lymphokine Activited Killer Cells on Cytotoxicity Against Lung Cancer Cells
下载PDF
导出
摘要 目的:观察抗原致敏树突状细胞(DC)联合淋巴因子激活的杀伤(LAK)细胞对肺腺癌细胞的杀伤作用。方法:采用密度梯度离心法分离出外周血单个核细胞(PBMC),常规诱导出DC、LAK细胞。倒置显微镜观察细胞的形态和增殖情况;应用流式细胞仪(FCM)测定细胞表型上变化鉴定这两种细胞。流式细胞仪检测DC经抗原冲击和未经抗原冲击后其表型变化;利用四甲基偶氮唑蓝(MTT)检测法把DC-LAK细胞和DC-LAK-A549细胞作为效应细胞,肺腺癌A549细胞作为靶细胞,进行杀伤试验。结果:①体外诱导单个核细胞培养出DC和LAK细胞。②共培养后DC-LAK细胞的免疫表型表达增加。抗原致敏DC联合LAK细胞(DC-A549-LAK)组的免疫表型表达与对照组相比更有显著性意义。③共培养细胞在增殖倍率上有显著意义。④MTT显示共培养后的LAK细胞杀伤肿瘤细胞活性增强,抗原致敏后DC-A549-LAK抗肿瘤效应增强更显著。结论:从外周血单个核细胞中诱导出具有典型形态和免疫表型的DC和LAK细胞。DC和LAK细胞共培养细胞,增殖活性、免疫表型、杀伤活性方面高于单纯培养的LAK细胞。抗原致敏后DC-A549-LAK抗肿瘤效应增强更显著。 Objective: To observe the effect of Dendritic Cells(DC) combined with Lymphokine Aetivited Kliller(LAK) Cells on Cytotoxicity against Lung Cancer Cells. Method. Density gradient centrifugation was used to separated peripheral blood mononuclear cells(PBMC), DC and LAK were conventional induced. Cell morphological and proliferation were observed by, inverted microscope . By FCM(flow cytometry measurement) to measure the change of phenotype and identify two kinds of cells. To detect the change of phenotype of DC by lysate antigen or no lysate antigen. Killing test was done by MTT. Result: (1)Invitro - induction PBMC cul- tured DC and LAK. (2)After co - culture, immune phenotype expression of DC - LAK was increased; Comparing to control group , there was signification different in immune phenotype expression of DC combined with LAK. (3)Co - cultured cells has significance in proliferic times. (4)MTT shows co - cultured LAK killed tumor cells ac- tivity increased, After lysate antigen, anti - tumor effect of DC - A549 - LAK markedly enhanced. Concision: With typical morphology and phenotype of DC and LAK were induced from PBMC. Co - cultured cells from DC and LAK were higher than simple culture LAK in proliferic activity, immune phenotype, killed tumor cells ac- tivity. After lysate antigen , anti - tumor effect of DC - A549 - LAK markedly enhanced.
出处 《内蒙古医学杂志》 2009年第8期897-900,共4页 Inner Mongolia Medical Journal
基金 内蒙古自治区卫生厅医疗卫生科研计划项目(2005061)
关键词 树突状细胞 淋巴因子激活的杀伤细胞 外周血单个核细胞 肺癌细胞株 抗肿瘤效应 Dentritic cell Lymphokine activated killer cells Peripheral blood mononuclear cells(PBMC) Lung cancer cell strains Anti-tumor effect
  • 相关文献

参考文献8

  • 1Kiyohara C, Yoshimasu K, Takayama K, et al. EPHXI Polymorphisms and the Risk of Lung Cancer: A HUGE Review[J]. Epidemiology, 2006,17(1) :89 - 99.
  • 2杨新静,黄建安,朱一蓓,胡玉敏,闫廷赞,张学光.CIK细胞对肺腺癌细胞株A549体内外杀瘤活性的实验研究[J].苏州大学学报(医学版),2006,26(4):553-555. 被引量:6
  • 3Alexanian R, Dimopoulos M. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin - 12 [ J ]. Gin Cancer Res, 2006, 159(42):4 035 - 4 041.
  • 4王艳萍,周清华.肺癌生物治疗研究进展[J].中国肺癌杂志,2003,6(6):423-429. 被引量:3
  • 5Ziske C , Schottker B, Take da T, et al . Analysis of cytotoxic activity of theCD4 + T lymphocytes generated by local immunotherapy[J]. Immunol Today, 2005, 73(1) : 110 - 116.
  • 6Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells[J]. Cell, 2001,105(21) : 263 - 269.
  • 7Girolomoni G, Ricciandi Lastagnoli P . Dend - ritic cells hold promise for immune-otherapy[J]. Immunol Today,, 1997, 18 (23):102- 110.
  • 8Vuillier F, Maloum K, Thomas EK, et al. Idiotype - pulsed dendritic cells are able to induce antigen - specific CTL - mediated protective tumor immunity[J]. Br J Haematol, 2003,120(2) : 248 - 250.

二级参考文献46

  • 1[1]Morse MA. Technology evaluation: BLP-25, Biomira Inc. Curr Opin Mol Ther,2001,3(1)∶102-105.
  • 2[2]Dickler MN, Ragupathi G, Liu NX, et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res,1999,5(10)∶2773-2779.
  • 3[3]Krug LM, Ragupathi G, Kris MG, et al. Development of a tetravalent small cell lung cancer (SCLC) vaccine containing GM2, fucosylGM1, globo H, and polysialic acid. Lung Cancer,2003,41(Suppl 2)∶S47.
  • 4[4]Vincent M, Smith C, Milroy R, et al. Results of a phase Ⅱ trail of EGF-P6 vaccine in patients with NSCLC. Lung Cancer,2003,41(Suppl 2)∶S47.
  • 5[5]Hanagirl T, Nagata Y, Mizukami M, et al. Vaccination with MAGE-3 peptides in patients with non-small cell lung cancer. Lung Cancer,2003,41(Suppl 2)∶S181.
  • 6[6]Tajima K, Kuzushima K , Endo H, et al. hTERT-specific CTL lysed lung cancer cell lines in an HLA-A24 restricted fasion. Lung Cancer,2003,41(Suppl 2)∶S182.
  • 7[7]Harper-Wynne C, Sumpter K, O'Brien MER, et al. Addition of SRL172 (mycobacterium vaccae) to standard chemotherapy in small cell lung (SCLC) confers no survival benefit: results of a randomized multicentre study. Lung Cancer,2003,41(Suppl 2)∶S181.
  • 8[8]Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A,2001,98(15)∶8809-8814 .
  • 9[9]Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol,2001,166(11)∶6555-6563.
  • 10[10]Grant SC, Kris MG, Houghton AN, et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res,1999,5(6)∶1319-1323.

共引文献7

同被引文献40

  • 1姚俊,杨欢,高宏君.热休克蛋白在肿瘤免疫中的研究进展[J].中国医疗前沿,2008,3(15):34-36. 被引量:1
  • 2赵春霞,赵荫涛,汪培华,肖啸,汪道文.重组腺相关病毒介导核心蛋白聚糖基因转染对SiHa细胞周期和凋亡的影响[J].癌症,2005,24(1):28-32. 被引量:6
  • 3鞠晓红,赵珍谊,方芳,马爱新.人脐血贴壁层细胞对脐血造血细胞体外扩增的作用[J].中国组织工程研究与临床康复,2007,11(7):1280-1281. 被引量:4
  • 4孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生出版社,2008:371.
  • 5Amy M.Hicks,Gregory Riedlinger,Mark C.Willingham,et al.Transferable anticancer innate immunity in spontaneous regression complete resistance mice.PNAS.2006;103(20):7753-7758.
  • 6Gattinoni L,Powell DJ Tr,Rosenberg SA,et al.Adoptive immunotherapy for cancer:building on success.Nat Rev Immunol.2006;6(5):383-393.
  • 7Williams LM,Rudensky AY.Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3.Nat Immunol.2007;8(3):277-284.
  • 8Tesniere A,Panaretakis T,Kepp O,Apetoh L,Ghiringhelli F,Zitvogel L,Kroemer G.Molecular characteristics of immunogenic cancer cell death.Cell Death Differ.《 2008;15(1):3-12.
  • 9Rescigno M,Avogadri F,Curigliano G.Challenges and prospects of immunotherapy as cancer treatment.Biochim Biophys Aeta.2007;1776(1):108-123.
  • 10McKee MD,Roszkowski JJ,Nishimura MI.T cell avidity and tumor recognition:implications and therapeutic strategies.J Transl Med.2005;3:35.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部